Search hospitals > North Carolina > Huntersville
Carolina BioOncology Institute
Claim this profileHuntersville, North Carolina 28078
Global Leader in Solid Tumors
Global Leader in Uterine Tumors
Conducts research for Cancer
Conducts research for Breast Cancer
Conducts research for Skin Cancer
94 reported clinical trials
2 medical researchers
Summary
Carolina BioOncology Institute is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Solid Tumors, Uterine Tumors, Cancer, Breast Cancer, Skin Cancer and other specialties. Carolina BioOncology Institute is involved with conducting 94 clinical trials across 75 conditions. There are 2 research doctors associated with this hospital, such as John Powderly, M.D. and John D. Powderly II, MD.Area of expertise
1Solid Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Uterine Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
Top PIs
John Powderly, M.D.Carolina BioOncology Institute3 years of reported clinical research
Expert in Solid Tumors
Expert in Uterine Tumors
39 reported clinical trials
68 drugs studied
John D. Powderly II, MDCarolina BioOncology Institute - Cancer Research Centre3 years of reported clinical research
Studies Solid Tumors
Studies Uterine Tumors
2 reported clinical trials
4 drugs studied
Clinical Trials running at Carolina BioOncology Institute
Solid Tumors
Uterine Tumors
Colorectal Cancer
Breast Cancer
Cancer
Pancreatic Cancer
Non-Small Cell Lung Cancer
Ovarian Cancer
Stomach Cancer
Lung Cancer
NUV-1511
for Solid Tumors
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Recruiting1 award Phase 1 & 2
AU-007
for Advanced Cancer
This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin was determined, (AU-007 Q2w plus a single loading dose of aldesleukin), AU-007 plus aldesleukin is also being administered with avelumab or nivolumab.
Recruiting1 award Phase 1 & 28 criteria
ABBV-303 + Budigalimab
for Solid Tumors
This trial is testing a new drug, ABBV-303, alone or with another drug, budigalimab, to treat adults with certain types of cancer that have returned or resisted other treatments. The drugs are given through an IV and aim to target and destroy cancer cells, possibly boosting the immune system's response.
Recruiting1 award Phase 14 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Carolina BioOncology Institute?
Carolina BioOncology Institute is a medical facility located in Huntersville, North Carolina. This center is recognized for care of Solid Tumors, Uterine Tumors, Cancer, Breast Cancer, Skin Cancer and other specialties. Carolina BioOncology Institute is involved with conducting 94 clinical trials across 75 conditions. There are 2 research doctors associated with this hospital, such as John Powderly, M.D. and John D. Powderly II, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.